C4 Therapeutics Statistics
Total Valuation
C4 Therapeutics has a market cap or net worth of $332.23 million. The enterprise value is $112.79 million.
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
C4 Therapeutics has 131.32 million shares outstanding. The number of shares has increased by 78.97% in one year.
| Current Share Class | 131.32M |
| Shares Outstanding | 131.32M |
| Shares Change (YoY) | +78.97% |
| Shares Change (QoQ) | +4.12% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 93.35% |
| Float | 100.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.27 |
| Forward PS | 15.98 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.17 |
| Quick Ratio | 4.99 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -47.62% and return on invested capital (ROIC) is -25.52%.
| Return on Equity (ROE) | -47.62% |
| Return on Assets (ROA) | -21.34% |
| Return on Invested Capital (ROIC) | -25.52% |
| Return on Capital Employed (ROCE) | -35.11% |
| Weighted Average Cost of Capital (WACC) | 18.53% |
| Revenue Per Employee | $310,356 |
| Profits Per Employee | -$875,894 |
| Employee Count | 104 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, C4 Therapeutics has paid $121,000 in taxes.
| Income Tax | 121,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.43% in the last 52 weeks. The beta is 3.16, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 3.16 |
| 52-Week Price Change | +2.43% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 3.26 |
| Relative Strength Index (RSI) | 33.44 |
| Average Volume (20 Days) | 3,066,367 |
Short Selling Information
The latest short interest is 46.58 million, so 35.47% of the outstanding shares have been sold short.
| Short Interest | 46.58M |
| Short Previous Month | 42.72M |
| Short % of Shares Out | 35.47% |
| Short % of Float | 46.33% |
| Short Ratio (days to cover) | 16.47 |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $32.28 million and -$91.09 million in losses. Loss per share was -$0.71.
| Revenue | 32.28M |
| Gross Profit | 28.68M |
| Operating Income | -101.95M |
| Pretax Income | -90.97M |
| Net Income | -91.09M |
| EBITDA | -100.51M |
| EBIT | -101.95M |
| Loss Per Share | -$0.71 |
Full Income Statement Balance Sheet
The company has $274.69 million in cash and investments and $55.25 million in debt, with a net cash position of $219.44 million or $1.67 per share.
| Cash & Investments | 274.69M |
| Total Debt | 55.25M |
| Net Cash | 219.44M |
| Net Cash Per Share | $1.67 |
| Equity (Book Value) | 228.17M |
| Book Value Per Share | 1.74 |
| Working Capital | 173.04M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$79.63 million and capital expenditures -$112,000, giving a free cash flow of -$79.74 million.
| Operating Cash Flow | -79.63M |
| Capital Expenditures | -112,000 |
| Depreciation & Amortization | 1.44M |
| Net Borrowing | n/a |
| Free Cash Flow | -79.74M |
| FCF Per Share | -$0.61 |
Full Cash Flow Statement Margins
Gross margin is 88.85%, with operating and profit margins of -315.86% and -282.22%.
| Gross Margin | 88.85% |
| Operating Margin | -315.86% |
| Pretax Margin | -281.85% |
| Profit Margin | -282.22% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
C4 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -78.97% |
| Shareholder Yield | -78.97% |
| Earnings Yield | -28.23% |
| FCF Yield | -24.05% |
Analyst Forecast
The average price target for C4 Therapeutics is $12.50, which is 394.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.50 |
| Price Target Difference | 394.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -14.52% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
C4 Therapeutics has an Altman Z-Score of -1.89 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.89 |
| Piotroski F-Score | 3 |